muraglitazar has been researched along with c-peptide in 2 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (c-peptide) | Trials (c-peptide) | Recent Studies (post-2010) (c-peptide) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 9,053 | 1,632 | 2,445 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belder, R; Chen, S; Cheng, PT; Devasthale, P; Egan, D; Farrelly, D; French, M; Gu, L; Hariharan, N; Harrity, T; Janovitz, E; Kunselman, L; Peters, A; Ponticiello, R; Staal, A; Swartz, J; Taylor, S; Tozzo, E; Welzel, G; Whaley, J; Zebo, R | 1 |
| Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K | 1 |
1 trial(s) available for muraglitazar and c-peptide
| Article | Year |
|---|---|
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain | 2009 |
1 other study(ies) available for muraglitazar and c-peptide
| Article | Year |
|---|---|
The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.
Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Experimental; Disease Progression; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Hypoglycemic Agents; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxazoles; Pancreas; PPAR alpha; PPAR gamma; Triglycerides | 2007 |